Glucagon-like peptide-1 receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. From Wikipedia
The first nonpeptide oral GLP-1 therapy, orforglipron, matches injectable drugs in weight-loss and glucose-control efficacy, with FDA filings planned for late 2025.
